Why the study?
Recent guidelines recommend systematic screening for perioperative myocardial injury using high-sensitivity cardiac troponin, but evidence regarding local screening programs is limited.
Does systematic screening for perioperative myocardial injury using hs-cTn predict death and MACCE in high-risk noncardiac surgery patients?
Does systematic screening for perioperative myocardial injury using hs-cTn predict death and MACCE in high-risk noncardiac surgery patients?
Systematic screening for perioperative myocardial injury using hs-cTn in high-risk noncardiac surgery patients reveals a high prevalence of PMI (15.7%) and significant 1-year mortality (11.2%), supporting guideline recommendations for routine screening.
Answers are grounded in this paper and cite their sources.
Supports feasibility of hs-cTn screening for PMI in one center; leaves open outcome benefits and generalizability.
Perioperative myocardial injury (PMI) is a common cardiac complication. Recent guidelines recommend its systematic screening using high-sensitivity cardiac troponin (hs-cTn). However, there is limited evidence of local screening programs. We conducted a prospective, single-center study aimed at assessing the feasibility and outcomes of implementing systematic PMI screening. Hs-cTn concentrations were measured before and after surgery. PMI was defined as a postoperative hs-cTnT of ≥14 ng/L, exceeding the preoperative value by 50%. All patients were followed-up during the hospitalization, at one month and one year after surgery. The primary outcome was the incidence of death and major cardiovascular and cerebrovascular events (MACCE). The secondary outcomes focused on the individual components of MACCE. We included two-thirds of all eligible high-risk patients and achieved almost complete compliance with follow-ups. The prevalence of PMI was 15.7%, suggesting a higher presence of cardiovascular (CV) antecedents, increased perioperative CV complications, and higher preoperative hs-cTnT values. The all-cause death rate was 1.7% in the first month, increasing up to 11.2% at one year. The incidence of MACCE was 9.5% and 8.6% at the same time points. Given the observed elevated frequencies of PMI and MACCE, implementing systematic PMI screening is recommendable, particularly in patients with increased cardiovascular risk. However, it is important to acknowledge that achieving optimal screening implementation comes with various challenges and complexities.
No takes yet. Share an insight, caveat, or question.
Popova et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: